TEVA Teva Pharmaceutical Industries Limited
Healthcare$34.61+1.58%ClosedMarket Cap: $40.30B
As of 2026-05-26
Valuation
P/E (TTM)
24.24
PEG
0.13
P/B
4.83
P/S
2.32
EV/EBITDA
16.19
DCF Value
$20.77
FCF Yield
4.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
52.0%
Operating Margin
19.4%
Net Margin
9.0%
ROE
20.8%
ROA
3.9%
ROIC
11.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $3.98B | 49.5% | $652.0M | $369.0M | $— | — |
| Q4 null | $4.71B | 56.4% | $300.0M | $480.0M | $— | — |
| FY null | $17.26B | 51.8% | $2.16B | $1.41B | $— | — |
| Q3 null | $4.48B | 51.4% | $882.0M | $433.0M | $— | — |
| Q2 null | $4.18B | 50.3% | $455.0M | $282.0M | $— | — |
| Q1 null | $3.89B | 48.2% | $519.0M | $214.0M | $— | — |
| Q4 null | $4.23B | 50.1% | $-29.0M | $-217.0M | $— | — |
| FY null | $16.54B | 48.7% | $-303.0M | $-1.64B | $— | — |
| Q3 null | $4.33B | 49.6% | $-51.0M | $-437.0M | $— | — |
| Q2 null | $4.16B | 48.6% | $-5.0M | $-846.0M | $— | — |
| Q1 null | $3.82B | 46.4% | $-218.0M | $-139.0M | $— | — |
| Q4 2023 | $4.46B | 54.2% | $756.0M | $463.0M | $0.41 | — |